Remote Identification of Autonomic Dysfunction in Childhood Cancer Survivors
This study is looking at new ways to find out if childhood cancer survivors, especially those who had acute lymphoblastic leukemia (ALL) or Hodgkin's lymphoma (HL), have a condition called cardiac autonomic dysfunction (AD). AD affects how your body controls things like heart rate and blood pressure. The study wants to see if a remote method, using a special heart rate monitor you wear, can identify AD as accurately as in-person tests. You would complete an in-person assessment called the Ewing battery, wear a biosensor heart monitor for 7 days, and fill out a questionnaire. The goal is to find AD sooner and potentially reduce health risks. This study is currently recruiting 188 participants who are 18 years or older and are part of the St. Jude Lifetime Cohort (SJLIFE).
- Study design
- This is an interventional study with a planned enrollment of 188 participants. It compares remote heart rate variability measurements to in-person assessments to identify cardiac autonomic dysfunction.
- What's involved
- You would complete a 60-90 minute in-person Ewing battery assessment, wear a biosensor heart monitor for 7 days after your visit, and complete a 20-30 minute questionnaire.
- Compensation
- Not stated in the trial record.
- Follow-up
- Heart rate variability will be measured for up to 7 days after your on-campus visit. Other primary endpoints are measured during the on-campus visit.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Assessment of Remote Approaches for Identification of Autonomic Dysfunction Among Survivors of Leukemia and Lymphoma
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Kirsten K Ness, PhD · PRINCIPAL_INVESTIGATOR · St. Jude Children's Research Hospital
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Heart rate variability (msec)Up to 7 days after the on-campus study visit
The standard deviation of normal-to-normal heartbeat intervals over a 24-hour period measured in milliseconds
- Abbreviated Composite Autonomic Symptom Score (0-100)During the on-campus study visit (Day 1)
Symptom burden-based questionnaire of six weighted domains (orthostatic intolerance, vasomotor, secretomotor, gastrointestinal bladder and pupillomotor) Abbreviated Composite Autonomic Symptom Score: * This questionnaire, administered during Day 1, generates a weighted score from 0 to 100, and questions fall into one of six domains: orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder, and pupillomotor function. Scores are determined by applying a simplified scoring algorithm. * Overall score interpretation: * \< 3 or less: Mild * 3-7: Moderate * \>7: Severe
- Ewing Score (0-5)During the on-campus study visit (Day 1)
Derived from sum of five individual autonomic test scores Ewing Battery Scoring: * This battery is administered during Day 1. Each test within the battery (5 tests total) is assigned a score of 0 (normal), 0.5 (borderline), or 1 (abnormal). * Overall score interpretation: * 0-1: Considered normal autonomic function * 1.5-2: Mild autonomic dysfunction * 2.5-3: Moderate autonomic dysfunction * 3.5-5: Severe autonomic dysfunction